. home.aspx



Amunix Raises $73 Million in Series A Financing Led by Omega Funds

March 04, 2020 / BioSpace

Amunix Pharmaceuticals Inc.  (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock, and Delian Capital.